Core Viewpoint - Zoom Communications reported disappointing fourth-quarter earnings, missing profit expectations and providing lower-than-expected profit guidance, leading to a significant drop in stock price [1] Financial Performance - Adjusted earnings per share for the fourth quarter were $1.44, falling short of the analyst consensus of $1.49 by $0.05 [1] - Revenue reached $1.25 billion, exceeding the expected $1.23 billion, with a year-over-year growth of 5.3% [1] - Enterprise revenue grew by 7.1% year-over-year to $757.3 million, and the number of customers contributing over $100,000 in revenue over the past 12 months increased by 9.3% to 4,468 [1] Future Guidance - For the first quarter of fiscal year 2027, the company expects adjusted earnings per share to be between $1.40 and $1.42, with a midpoint of $1.41, which is below the analyst consensus of $1.45 [1] - Revenue guidance for the first quarter is projected to be between $1.22 billion and $1.23 billion, with a midpoint of $1.23 billion, slightly above the consensus of $1.22 billion [1] - For the full fiscal year 2027, adjusted earnings per share guidance is set between $5.77 and $5.81, with a midpoint of $5.79, significantly lower than the consensus of $5.97 [1] - Revenue guidance for the full year is projected at $5.065 billion to $5.075 billion, with a midpoint of $5.070 billion, exceeding the analyst consensus of $4.838 billion [1]

Core Viewpoint - Zoom Communications reported disappointing fourth-quarter earnings, missing profit expectations and providing lower-than-expected profit guidance, leading to a significant drop in stock price [1] Financial Performance - Adjusted earnings per share (EPS) for the fourth quarter were $1.44, falling short of the analyst consensus of $1.49 by $0.05 [1] - Revenue reached $1.25 billion, exceeding the expected $1.23 billion, with a year-over-year growth of 5.3% [1] - Enterprise revenue grew by 7.1% year-over-year to $757.3 million, and the number of customers contributing over $100,000 in revenue over the past 12 months increased by 9.3% to 4,468 [1] Future Guidance - For the first quarter of fiscal year 2027, Zoom expects adjusted EPS to be between $1.40 and $1.42, with a midpoint of $1.41, which is below the analyst consensus of $1.45 [1] - The company anticipates first-quarter revenue to be between $1.22 billion and $1.23 billion, with a midpoint of $1.23 billion, slightly above the consensus of $1.22 billion [1] - For the full fiscal year 2027, Zoom's adjusted EPS guidance is set at $5.77 to $5.81, with a midpoint of $5.79, significantly lower than the consensus of $5.97 [1] - However, the revenue guidance for the full year is projected to be between $5.065 billion and $5.075 billion, with a midpoint of $5.070 billion, surpassing the analyst consensus of $4.838 billion [1]

Core Viewpoint - The company has issued a conservative profit guidance for 2026, indicating that annual profits may fall below Wall Street expectations due to various external factors [1] Industry Policy and Environment - The U.S. government's budget cuts for academic research institutions are expected to continue until 2026, leading to cautious equipment procurement by downstream research clients and biotechnology companies [1] - The reduction in research funding by the Trump administration directly impacts the company's core customer base, suppressing short-term demand [1] - Increased competition pressure arises from U.S. trade policies and rising supply chain costs between the U.S. and China, particularly affecting the company's lower-margin businesses in the domestic mid-range market [1] Operating Conditions - Despite a significant rebound in demand from pharmaceutical clients in Q4 2025, high-end instrument equipment demand remains sluggish due to budget constraints faced by U.S. government and academic clients [2] - The analytical instruments business experienced an 11.2% year-over-year profit decline in 2025, reflecting growth pressures in this sector [2] Company Status - The company has announced the closure of its facilities in Franklin, Massachusetts, and Asheville, North Carolina, with plans to complete these adjustments by the end of 2026 [3] - These operational changes aim to optimize global efficiency and concentrate resources on higher-margin businesses, although they may incur restructuring costs and impact market confidence in the short term [3] Institutional Views - Some institutions, such as CMB International, maintain a "buy" rating, believing that long-term demand in biopharmaceuticals and strategic acquisitions will support competitiveness, despite concerns over weak short-term guidance [4]